Abacus FCF Advisors LLC Boosts Stock Holdings in Hologic, Inc. (NASDAQ:HOLX)

Abacus FCF Advisors LLC lifted its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 46.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 26,340 shares of the medical equipment provider's stock after acquiring an additional 8,308 shares during the period. Abacus FCF Advisors LLC's holdings in Hologic were worth $1,899,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in HOLX. General Partner Inc. bought a new stake in Hologic in the fourth quarter worth approximately $26,000. Groupama Asset Managment grew its position in shares of Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock worth $27,000 after buying an additional 2,999 shares during the period. Venturi Wealth Management LLC increased its stake in shares of Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after acquiring an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 260 shares during the period. Finally, Smartleaf Asset Management LLC boosted its stake in Hologic by 36.9% during the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after acquiring an additional 159 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Leerink Partners lowered shares of Hologic from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Royal Bank of Canada decreased their target price on Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a research report on Thursday, February 6th. Leerink Partnrs lowered Hologic from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 6th. William Blair restated an "outperform" rating on shares of Hologic in a report on Thursday, February 6th. Finally, Raymond James reiterated an "outperform" rating and issued a $90.00 target price (down from $95.00) on shares of Hologic in a report on Thursday, February 6th. Eleven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, Hologic currently has a consensus rating of "Hold" and a consensus price target of $84.62.

Hologic Stock Performance

Shares of Hologic stock traded up $0.69 during mid-day trading on Friday, hitting $57.85. 4,235,273 shares of the stock were exchanged, compared to its average volume of 1,911,277. Hologic, Inc. has a 12 month low of $56.27 and a 12 month high of $84.67. The company has a 50-day simple moving average of $62.47 and a 200 day simple moving average of $71.49. The company has a market capitalization of $12.98 billion, a P/E ratio of 18.25, a P/E/G ratio of 2.14 and a beta of 0.82. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.78 and a current ratio of 3.49.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Sell-side analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.